Quick Answer
PROVECTUS BIOPHARMACEUTICALS, INC. reported Stockholders Equity of -$6.30 million for fiscal year 2025.
PROVECTUS BIOPHARMACEUTICALS, INC. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$6.30M | -5.7% |
| 2024 | -$5.96M | +21.5% |
| 2023 | -$7.59M | -21.9% |
| 2022 | -$6.23M | -48.7% |
| 2021 | -$4.19M | +86.1% |
| 2020 | -$30.21M | -25.5% |
| 2019 | -$24.07M | -38.2% |
| 2018 | -$17.42M | -73.8% |
| 2017 | -$10.02M | -388.8% |
| 2016 | $3.47M | -78.7% |
| 2015 | $16.32M | -35.2% |
| 2014 | $25.19M | +280.0% |
| 2013 | $6.63M | +50.9% |
| 2012 | $4.39M | -56.2% |
| 2011 | $10.02M | -6.4% |
| 2010 | $10.70M | +13.7% |
| 2009 | $9.41M | -6.5% |
| 2008 | $10.06M | -32.2% |
| 2007 | $14.83M | -4.5% |
| 2006 | $15.52M | +7.9% |
| 2005 | $14.39M | +57.0% |
| 2004 | $9.16M | -10.6% |
| 2003 | $10.25M | -12.6% |
| 2002 | $11.72M | +1461693.0% |
| 2002 | $802.00 | — |
| 2002 | $0.00 | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$6.15M | -13.4% | -4.8% |
| June 30, 2025 | -$5.87M | +21.9% | -15.1% |
| March 31, 2025 | -$5.10M | +31.5% | +14.4% |
| December 31, 2024 | -$5.96M | +21.5% | -9.9% |
| September 30, 2024 | -$5.42M | +27.9% | +27.8% |
| June 30, 2024 | -$7.51M | -3.0% | -0.9% |
| March 31, 2024 | -$7.45M | -6.4% | +1.9% |
| December 31, 2023 | -$7.59M | -21.9% | -1.0% |
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -5.7% in Stockholders Equity compared to the prior fiscal year.
- The most recent figure is from PROVECTUS BIOPHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: